VICTORIA, BC , Aug. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX ) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphereTM technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2024.
All dollar values are in U.S. dollars unless stated otherwise.
"Our eosinophilic esophagitis ("EoE") clinical program is making excellent progress, as additional safety and efficacy data from our ongoing RESOLVE study continues to suggest that EP-104GI could represent a significant improvement over currently approved therapies for this debilitating condition," said Dr. James Helliwell , CEO of Eupraxia. "In addition, during the second quarter, we presented data at two medical meetings highlighting the potential of our candidate for the treatment of knee osteoarthritis ("OA"), EP-104IAR, which also holds the potential to advance the current standard of care in OA.
" Dr. Helliwell continued, "Looking ahead, we anticipate reporting new data from the fourth cohort of the RESOLVE study in the near term and we continue to engage prospective partners for possible licensing of the EP-10IAR program. We look forward to engaging with the U.
S. Food and Drug Administration in the fourth quarter of 2024 on the EP-104GI program and potentially expanding our gastrointestinal trials into the U.S.
With two clinical-stage assets each hav.